Literature DB >> 22114905

Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning.

Daniel A Nadeau1, Carlos Campos, Marcus Niemeyer, Timothy Bailey.   

Abstract

OBJECTIVE: FlexTouch * (FT) is a new prefilled insulin pen with no push-button extension at any set dose and a low activation force that is designed to improve ease of use and insulin administration. This paper reports the results of two usability studies assessing perceptions of FT compared with KwikPen † (KP)and SoloStar ‡ (SS) among healthcare professionals (HCPs; both physicians and nurses) and people with diabetes (both insulin pen-experienced and insulin pen-naïve). RESEARCH DESIGN AND METHODS: Participants were randomly assigned to start with FT or KP in one study and FT or SS in the other. Participants performed injections at different doses (20, 40 and 60 International Units [IU] in the FT vs. KP study or 20, 40 and 80 IU in the FT vs. SS study) into a foam cushion before answering questions on ease of use, teaching and learning, confidence and preference.
RESULTS: A total of 59 people with diabetes and 61 HCPs took part in the FT vs. SS study, and 79 people with diabetes and 81 HCPs took part in the FT vs. KP study. Considerably more patients and HCPs rated FT as very/fairly easy to inject with than KP or SS, particularly at the maximum dose (≥80% vs. ≤38% and ≤23%, respectively), and more were very/rather confident in the ability to manage daily insulin injections with FT than KP or SS. Overall, FT was rated significantly higher for ease of teaching and learning to use than KP or SS (all p < 0.001 vs. FT), and was preferred for teaching and learning compared with KP or SS (≥39% vs. ≤4% and ≤6%, respectively). More patients and HCPs would recommend FT (≥95%) than KP (≤72%) or SS (≤71%). The same pattern was generally seen across physicians, nurses, insulin pen-experienced and pen-naïve participants.
CONCLUSIONS: The findings suggest that devices such as FT are easy to use and can be prescribed with relatively few training needs, which may improve ease of insulin initiation, increase pen use, and ultimately improve treatment adherence. A limitation of the usability questionnaire used in this study is that it did not assess the factors that influence preference. Further analyses could be conducted to determine the factors that appeal to different users.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22114905     DOI: 10.1185/03007995.2011.644427

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  10 in total

1.  Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.

Authors:  Glenn Matfin; Kate Van Brunt; Alan G Zimmermann; Rebecca Threlkeld; Debra A Ignaut
Journal:  J Diabetes Sci Technol       Date:  2015-04-21

2.  FlexTouch: An Insulin Pen-Injector with a Low Activation Force Across Different Insulin Formulations, Needle Technologies, and Temperature Conditions.

Authors:  Niels Gudiksen; Thibaud Hofstätter; Birgitte B Rønn; Thomas Sparre
Journal:  Diabetes Technol Ther       Date:  2017-07-13       Impact factor: 6.118

3.  Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus.

Authors:  Anna Rydén; Stephanie Chen; Emuella Flood; Beverly Romero; Susan Grandy
Journal:  Patient       Date:  2017-08       Impact factor: 3.883

4.  Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience.

Authors:  Ken Fujioka; Thomas Sparre; Lily Yong-Hui Sun; Susanne Krogsgaard; Robert F Kushner
Journal:  J Diabetes Sci Technol       Date:  2015-07-16

5.  Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.

Authors:  Louis S Matza; Kristina S Boye; Katie D Stewart; Evan W Davies; Rosirene Paczkowski
Journal:  BMC Health Serv Res       Date:  2017-11-25       Impact factor: 2.655

6.  Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism.

Authors:  Eric Zijlstra; Hans-Veit Coester; Tim Heise; Leona Plum-Mörschel; Ole Rasmussen; Tord Rikte; Line Kynemund Pedersen; Marianne Qvist; Thomas Sparre
Journal:  Diabetes Obes Metab       Date:  2018-01-25       Impact factor: 6.577

7.  Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).

Authors:  Louis S Matza; Kristina S Boye; Katie D Stewart; Karin S Coyne; Paula K Wullenweber; Katelyn N Cutts; Jessica B Jordan; Qianqian Wang; Maria Yu; Brooke M Currie; Karen G Malley; K Jack Ishak; Ryan T Hietpas; Luis-Emilio García-Pérez
Journal:  Diabetes Obes Metab       Date:  2019-12-19       Impact factor: 6.577

Review 8.  The Review of Insulin Pens-Past, Present, and Look to the Future.

Authors:  Małgorzata Masierek; Katarzyna Nabrdalik; Oliwia Janota; Hanna Kwiendacz; Maksymilian Macherski; Janusz Gumprecht
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 5.555

9.  Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).

Authors:  Athena Philis-Tsimikas; Meryl Brod; Marcus Niemeyer; Ann Marie Ocampo Francisco; Jeffrey Rothman
Journal:  Adv Ther       Date:  2013-06-29       Impact factor: 3.845

Review 10.  A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.

Authors:  Colin H Ridyard; Dalia M M Dawoud; Lorna V Tuersley; Dyfrig A Hughes
Journal:  Patient       Date:  2016-08       Impact factor: 3.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.